Skip to main
CNMD

CONMED (CNMD) Stock Forecast & Price Target

CONMED (CNMD) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 0%
Buy 17%
Hold 83%
Sell 0%
Strong Sell 0%

Bulls say

Conmed Corp has demonstrated substantial growth potential through its innovative product lines, particularly with the BioBrace, which is expected to see a full market release of a new rotator cuff repair device in the latter half of 2025. The company's Foot & Ankle segment reported double-digit growth despite facing supply constraints, indicating resilience and a potential easing of these issues. Furthermore, management's conservative revenue guidance suggests a commitment to gradual revenue improvement, supported by strong performance in high-growth areas, including AirSeal and Foot & Ankle products.

Bears say

Conmed Corp has experienced a significant year-to-date decline of approximately 27%, attributed to ongoing challenges as the company undertakes a turnaround strategy. The company's current valuation is projected at 15 times the fiscal year 2025 earnings per share estimate of $4.46, reflecting a downward adjustment from a previous price target based on recent stock performance. Furthermore, capital weakness, especially on the international front, is linked to difficult year-over-year comparisons rather than an overall contraction in hospital capital budgets, indicating underlying concerns in market performance and competitive positioning.

CONMED (CNMD) has been analyzed by 6 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 17% recommend Buy, 83% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CONMED (CNMD) Forecast

Analysts have given CONMED (CNMD) a Hold based on their latest research and market trends.

According to 6 analysts, CONMED (CNMD) has a Hold consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CONMED (CNMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.